208 related articles for article (PubMed ID: 31628858)
1. Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
Qin S; Eugene AR; Liu D; Zhang L; Neavin D; Biernacka JM; Yu J; Weinshilboum RM; Wang L
Clin Pharmacol Ther; 2020 Mar; 107(3):662-670. PubMed ID: 31628858
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
7. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
[TBL] [Abstract][Full Text] [Related]
8. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
Ji Y; Hebbring S; Zhu H; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Zeng Z; Schaid D; Mrazek DA; Kaddurah-Daouk R; Weinshilboum RM
Clin Pharmacol Ther; 2011 Jan; 89(1):97-104. PubMed ID: 21107318
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
10. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
[TBL] [Abstract][Full Text] [Related]
11. SLC6A4 variation and citalopram response.
Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
[TBL] [Abstract][Full Text] [Related]
12. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
[TBL] [Abstract][Full Text] [Related]
13. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.
Keers R; Uher R; Huezo-Diaz P; Smith R; Jaffee S; Rietschel M; Henigsberg N; Kozel D; Mors O; Maier W; Zobel A; Hauser J; Souery D; Placentino A; Larsen ER; Dmitrzak-Weglarz M; Gupta B; Hoda F; Craig I; McGuffin P; Farmer AE; Aitchison KJ
Pharmacogenomics J; 2011 Apr; 11(2):138-45. PubMed ID: 20212518
[TBL] [Abstract][Full Text] [Related]
14. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
[TBL] [Abstract][Full Text] [Related]
15. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
[TBL] [Abstract][Full Text] [Related]
16. Genotyping of patients treated with selective serotonin reuptake inhibitors.
Solhaug V; Haslemo T; Kringen MK; Molden E; Dietrichs ES
Tidsskr Nor Laegeforen; 2022 Sep; 142(13):. PubMed ID: 36164782
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
[TBL] [Abstract][Full Text] [Related]
18. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.
Nonen S; Kato M; Takekita Y; Wakeno M; Sakai S; Serretti A; Kinoshita T
J Clin Psychopharmacol; 2016 Feb; 36(1):27-31. PubMed ID: 26674707
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
Singh AB; Bousman CA; Ng CH; Byron K; Berk M
Transl Psychiatry; 2012 Nov; 2(11):e198. PubMed ID: 23188198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
